Friday, July 31, 2026

Is Russia Protecting North Korea’s Illegal Acts?

The Ministry of Unification expressed deep regret...

2026: New South-North Cooperation Guidelines – What You Need to Know About Humanitarian Aid Expansion

The Ministry of Unification revises inter-Korean project regulations, enhancing support while tightening management and transparency requirements.

Could Trump’s Return Boost Inflation to New Heights?

Yahoo Finance reported on June 20 that...

Tag: Eli Lilly

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Eli Lilly’s Retatrutide: The Revolutionary Triple Hormone Treatment for Obesity – What You Need to Know

Eli Lilly's retatrutide shows promising results in Phase 3 trials, aiming for FDA approval for obesity and related conditions in 2027.

Unlocking the Future of Neuroscience: AriBio’s Partnership with Lilly TuneLab for Advanced AI Drug Development

AriBio partners with Eli Lilly's AI platform, Lilly TuneLab, to enhance drug development for neurodegenerative diseases using advanced AI.

Eli Lilly’s New Weight Loss Pill Foundayo: A Game Changer in the GLP-1 Market?

The FDA has approved Eli Lilly's oral obesity drug Foundayo, enhancing competition in the weight loss market with flexible dosing.

Samsung Biologics Partners with Eli Lilly: How This Open Innovation Hub Will Transform K-Bio by 2027

Samsung Biologics partners with Eli Lilly to create a biotech innovation hub in Korea, enhancing growth opportunities for local firms.

South Korea’s Pharmaceutical Future: 500 Million USD Investment from Eli Lilly to Boost K-Bio Innovation

South Korea partners with Eli Lilly to boost biotech and pharma industries, investing $500M to enhance innovation and healthcare access.

Celltrion’s Strategic Move: How Local Production in the U.S. Can Mitigate Tariff Risks

Celltrion outlines its Branchburg facility's operations and plans to mitigate tariff risks by establishing local production and a supply system.

Eli Lilly vs. Novo Nordisk: A $1.2 Billion Bet Reveals Two Very Different Futures for Obesity Drugs

Eli Lilly and Novo Nordisk are pursuing different strategies in the obesity treatment market, focusing on expansion versus core strengths.

Nvidia and Eli Lilly: How AI is Revolutionizing Drug Development in 2026

Nvidia partners with Eli Lilly to enhance AI in drug development, aiming to revolutionize the biotech industry.

Rising Use of GLP-1 Drugs May Be Linked to Rare Pancreatitis Cases, Study Finds

Reports of acute pancreatitis linked to GLP-1 diabetes drugs surge in the UK, prompting investigations and conflicting academic findings.

Ozempic Maker Swaps CEO, Bets $2.2B on New Obesity Drug Fight

Novo Nordisk's leadership change aims to reclaim its obesity treatment market share amid competition from Eli Lilly's Mounjaro.

New Study: Mounjaro Helps Users Drop Over 50 Pounds

Eli Lilly's Mounjaro leads U.S. obesity drug market, outperforming semaglutide in weight loss efficacy and safety.

Novo Nordisk Pushes for First Oral Obesity Drug Approval

Novo Nordisk seeks FDA approval for oral Wegovy, potentially the first oral obesity treatment, amid competition with Eli Lilly.

Eli Lilly’s Oral GLP-1 Shows 7.9% Weight Loss in Type 2 Diabetes Trial

Eli Lilly's orforglipron shows promise in Phase 3 trials for diabetes and obesity, offering an oral alternative to injectables.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.